Mark E. Schurdak, Ph.D.
|
|||||||||||||||||||||||||
Ph.D. in Pharmacology, Baylor College of Medicine | |||||||||||||||||||||||||
Contact10045 Biomedical Science Tower 3
3501 Fifth Avenue Pittsburgh, Pennsylvania 15260 Phone: 412-648-3090 E-mail: mes234@pitt.edu Website: upddi.pitt.edu |
Research SummaryMy research interests center on applying a systems biology/pharmacology approach to develop more effective drug discovery strategies that utilize integrated phenotype/function-based analysis (where all targets involved are functioning in a more physiologic relevant environment) and to better understand the molecular mechanisms that cause drugs to succeed or fail in the clinic. Recent PublicationsGough A, Stern AM, Maier J, Lezon T, Shun T-Y, Chennubhotla C, Schurdak ME, Haney SA and Taylor DL (2017). Biologically relevant heterogeneity: Metrics and practical insights. SLAS Discovery 22:213-227 PMID: 28231035 D’Aiuto L, Williamson K, Dimitrion P, McNulty J, Brown CE, Dokuburra CB, Nielsen AJ, Lin WJ, Piazza P, Schurdak ME, Wood J, Yolken RH, Kinchington PR, Bloom DC, Nimgaonkar VL. (2017) Comparison of three cell-based drug screening platforms for HSV-1 infection. Antiviral Res 2:136-140. LaPorte MG, Wang Z, Colombo R, Garzan A, Peshkov VA, Liang M, Johnston PA, Schurdak ME, Sen M, Camarco DP, Hua Y, Pollock NI, Lazo JS, Grandis JR, Wipf P, Huryn DM (2016) Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors Bioorg Med Chem Lett 26(15):3581-5 Grants
|